Physician profile
John C Chaney
NPI 1346270592
$22,200.84
in general payments reported to CMS, 2019-2025
24 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,187 · 2021: $2,497 · 2022: $992 · 2023: $397 · 2024: $391 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,842 · Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,841.96 |
| Food and Beverage | $989.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,075.54 | 2019-2023 | Ofev |
| Ethicon INC. | $2,376.80 | 2019-2024 | Monarch Platform |
| Medical Device Business Services, INC. | $2,001.43 | 2025 | Monarch |
| Electromed, INC. | $891.65 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $131.84 | 2023-2024 | |
| Grifols USA, LLC | $116.39 | 2019-2022 | |
| Dexcom, INC. | $97.68 | 2023 | Dexcom G6 Transmitter |
| Insmed, INC. | $57.31 | 2024 | Arikayce |
| Astellas Pharma US INC | $54.81 | 2022 | |
| Genzyme Corporation | $50.82 | 2020-2021 | |
| Glaxosmithkline, LLC. | $49.17 | 2019 | |
| Inspire Medical Systems, INC. | $43.09 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $39.64 | 2019-2022 | |
| Philips North America LLC | $32.77 | 2019-2020 | |
| Boston Scientific Corporation | $24.56 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coaptech, INC. | $21.99 | 2021 | |
| Watermark Medical, INC. | $20.57 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.99 | 2022 | |
| Auris Health, INC. | $19.57 | 2019 | |
| Eisai INC. | $16.72 | 2020 | |
| Axsome Therapeutics, INC. | $16.27 | 2023 | Sunosi |
| Inogen, INC. | $15.72 | 2022 | |
| Resmed Corp | $13.75 | 2024 | |
| Fisher & Paykel Healthcare INC | $12.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.